Danish biotech company SNIPR Biome has secured Bill & Melinda Gates Foundation financing. Details of the funding, including the total amount raised, were not disclosed.
The funding aims to advance SNIPR Biome's microbial gene therapy platform with a focus on managing Environmental Enteric Dysfunction (EED), a condition prevalent in pregnant women, by reducing gut entero-pathogen burden. The company aims to generate CRISPR-armed phages (CAPs) from its phage library that has a broad antibacterial activity on Escherichia coli and Klebsiella pneumoniae strains sourced from sites in low- and middle-income countries. SNIPR Biome’s existing CRISPR-armed phage cocktail (SNIPR001) will be leveraged in this project.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.